{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% confidence interval (CI) was not estimable due to short follow-up by participants.","groupId":"OG000","lowerLimit":"13.86","upperLimit":"NA","value":"18.43"},{"comment":"Median and 95% CI was not estimable due to short follow-up by participants.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"283"},{"groupId":"OG001","value":"286"}],"units":"Participants"}],"description":"PFS: duration from date of randomization to either progressive disease (PD)/death, whichever occurred first. PD: defined as meeting any 1 of following criteria: Increase of greater than equal to (\\>=)25 percent(%) in level of serum M-protein from lowest response value and absolute increase must be \\>=0.5 gram per deciliter (g/dL); Increase of \\>=25% in 24-hours(h) urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \\>=200 mg/24h; Only in participants without measurable serum and urine M-protein levels: increase of \\>=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be \\>10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \\>11.5 mg/dL) attributed solely to plasma cell (PC) proliferative disorder.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received lenalidomide at a dose of 25 milligrams (mg) orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone at a total dose of 40 mg weekly (or 20 mg weekly for participants greater than \\[\\>\\] 75 years old or with a body mass index less than \\[\\<\\] 18.5 kilograms per meter square \\[kg/m\\^2\\]).","id":"OG000","title":"Lenalidomide, Low-dose Dexamethasone (Rd)"},{"description":"Participants received daratumumab 16 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks, each 28-day cycle); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks, each 28-day cycle); once only on Day 1 during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone was administered at a total dose of 40 mg weekly (or 20 mg weekly for participants \\>75 years old or with a body mass index \\< 18.5 kg/m\\^2).","id":"OG001","title":"Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat (ITT) analysis set included all participants who were randomly assigned to the daratumumab, lenalidomide, dexamethasone (DRd) or lenalidomide, low-dose dexamethasone (Rd) group.","reportingStatus":"POSTED","timeFrame":"From randomization to either disease progression or death whichever occurs first (up to 21 months)","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}